Equillium, Inc.

EQ · Nasdaq · SIC 2834: Pharmaceutical Preparations
158
SEC Filings

Business Summary

PART I Item 1. Bus iness. Overview We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. Our primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. EQ504 is a preclinical-stage, novel AhR modulator that in multiple translational models has been shown to have a therapeutically beneficial impact indu...

Next Earnings

Q2 FY2026 — expected 2026-09-11

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionEQdiscussed_in_filing Cybersecurity
topic_mentionEQdiscussed_in_filing Cybersecurity
topic_mentionEQdiscussed_in_filing Healthcare & Bio
topic_mentionEQdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-252025-12-310001193125-26-124143EDGAR87K words
2025-03-272024-12-310000950170-25-045726EDGAR—
2024-03-252023-12-310000950170-24-035919EDGAR—
2023-03-232022-12-310000950170-23-009492EDGAR—
2022-03-232021-12-310000950170-22-004407EDGAR—
2021-03-242020-12-310001564590-21-015103EDGAR—
2020-03-262019-12-310001564590-20-013207EDGAR—
2019-03-272018-12-310001564590-19-009580EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001193125-25-280202EDGAR65K words
2025-08-142025-06-300000950170-25-108834EDGAR—
2025-05-142025-03-310000950170-25-071389EDGAR—
2024-11-132024-09-300000950170-24-126322EDGAR—
2024-08-082024-06-300000950170-24-093949EDGAR—
2024-05-092024-03-310000950170-24-056960EDGAR—
2023-11-082023-09-300000950170-23-061108EDGAR—
2023-08-092023-06-300000950170-23-040583EDGAR—
2023-05-112023-03-310000950170-23-021236EDGAR—
2022-11-142022-09-300000950170-22-025052EDGAR—
2022-08-152022-06-300000950170-22-017399EDGAR—
2022-05-122022-03-310000950170-22-009669EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-250001193125-26-124107EDGAR2K words
2026-03-130001193125-26-105083EDGAR—
2025-11-130001193125-25-280173EDGAR—
2025-10-060001193125-25-231860EDGAR—
2025-09-190001193125-25-209068EDGAR—
2025-09-040000950170-25-113023EDGAR—
2025-08-110001193125-25-177510EDGAR—
2025-08-040001193125-25-172207EDGAR—
2025-06-130000950170-25-086155EDGAR—
2025-05-220001193125-25-125153EDGAR—

158 total filings indexed. 128 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001746466
TickerEQ
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 95543a34dc45aeac689fa690f915b6b2bc8430a4d351771ca6c9f8c02f529323
parent: 1050e3334f48b25aa48c131f7a1c5eb5aa9e9a3bc54fa73a65812326667b2356
content hash: ac454eb22f24ae94f1abb6d5dae26098e1760139c76b618e6c98a59624e4f0a5
signed: 2026-04-13T04:44:53.325Z
sources: 20 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf